AHCPR Becomes AHRQ, But Call It ARC

The association between use of a telegenetics service and lower likelihood of germline testing was statistically significant among black veterans with cancer, according to a recent retrospective cohort study.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Zanubrutinib appears to produce significantly better progression-free survival and overall cardiac safety compared with ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Data from a cohort study suggest MGMT promoter methylation could serve as a stratification factor for patients with low-grade and anaplastic gliomas harboring IDH–wild-type or IDH-mutant and co-deleted tumors.

The safety review committee of the phase 1/2 Acclaim-1 trial identifies a recommended phase 2 dose of quaratusugene ozeplasmid plus osimertinib in the management of advanced non–small cell lung cancer.